{
    "clinical_study": {
        "@rank": "100857", 
        "arm_group": [
            {
                "arm_group_label": "Rivaroxaban"
            }, 
            {
                "arm_group_label": "Phenprocoumon"
            }
        ], 
        "brief_summary": {
            "textblock": "This prospective cohort study will provide information about: characteristics of Rivaroxaban\n      use in patients who are prescribed Rivaroxaban for the first time compared to patients who\n      are prescribed Phenprocoumon for the first time, the occurrence of intracranial haemorrhage,\n      gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease."
        }, 
        "brief_title": "Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Embolism", 
        "condition_browse": {
            "mesh_term": [
                "Embolism", 
                "Pulmonary Embolism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients between 2 and 89 years, who have been prescribed for the first time either\n             Rivaroxaban or Phenprocoumon.\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "89 Years", 
            "minimum_age": "2 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All male and female patient aged 2 to 89 years who have been enrolled in the database\n        (GePaRD) for at least 1 year."
            }
        }, 
        "enrollment": {
            "#text": "20000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947959", 
            "org_study_id": "16159", 
            "secondary_id": "XA1201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rivaroxaban", 
                "description": "Patients who have been prescribed Rivaroxaban for the first time, divided in two subgroups: Na\u00efve and Non Na\u00efve. The Non Na\u00efve are also divided in two subgroups: Recent switchers and Distant switchers.", 
                "intervention_name": "Rivaroxaban (Xarelto, Bay59-7939)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Phenprocoumon", 
                "description": "Patients who have been prescribed Phenprocoumon for the first time, divided in two subgroups: Na\u00efve and Non Na\u00efve. The Non Na\u00efve are also divided in two subgroups: Recent switchers and Distant switchers", 
                "intervention_name": "Phenprocoumon", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Phenprocoumon"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rivaroxaban,", 
            "Pulmonary Embolism,", 
            "Venous Thrombosis,", 
            "Venous Thromboembolism,", 
            "Acute Coronary Syndrome,", 
            "Intracranial Hemorrhages,", 
            "Gastrointestinal Hemorrhage,", 
            "Phenprocoumon"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Germany"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Proposed Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice in Germany", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Crude incidence rates will be estimated for each of the three primary adverse outcomes in both cohorts. Age- and sex-adjusted rate ratios with 95% CIs will be estimated for each of the three primary adverse outcomes comparing Rivaroxaban with VKA using Poisson regression analysis.", 
                "measure": "Major bleedings: Intracranial haemorrhage, Gastrointestinal bleeding and Urogenital bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "The two cohorts will be followed up from the index date until 12 months after the end of the extended enrollment period for potential outcomes"
            }, 
            {
                "measure": "Drug utilization pattern", 
                "safety_issue": "No", 
                "time_frame": "The two cohorts will be followed up from the index date until 12 months after the end of the extended enrollment period for potential outcomes"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947959"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Non-infective liver disease", 
                "safety_issue": "Yes", 
                "time_frame": "The two cohorts will be followed up from the index date until 12 months after the end of the extended enrolment period for potential outcomes"
            }, 
            {
                "measure": "Effectiveness outcomes: Deep vein thrombosis and Pulmonary embolism, Ischaemic stroke, Myocardial infarction, Death", 
                "safety_issue": "No", 
                "time_frame": "The two cohorts will be followed up from the index date until 12 months after the end of the extended enrolment period for potential outcomes"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}